Literature DB >> 6637463

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

M Szaff, N Høiby, E W Flensborg.   

Abstract

During the period 1971-75, 51 cystic fibrosis (CF) patients who contracted chronic P. aeruginosa infection were treated at the Danish CF centre with anti-pseudomonas chemotherapy only when their clinical condition deteriorated considerably. During the period 1976-80, 58 CF patients who contracted chronic P. aeruginosa infection were treated at the Danish CF centre with anti-pseudomonas chemotherapy on a regular basis every 3 months. Each routine 24 day-course of chemotherapy consisted of tobramycin in combination with carbenicillin or other beta-lactam antibiotics with activity against P. aeruginosa. In case of allergy or resistant strains monotherapy with tobramycin was used. The 5-year survival of CF patients from the time of the onset of the chronic P. aeruginosa infection increased from 54% in the first period to 82% in the second period (p less than 0.05), and lung function (peak expiratory flow rate) also improved significantly. It is concluded that intensive "maintenance" chemotherapy against P. aeruginosa improves survival and quality of life of CF patients although permanent eradication of P. aeruginosa is not accomplished.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6637463     DOI: 10.1111/j.1651-2227.1983.tb09789.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  61 in total

Review 1.  Intravenous antibiotics at home in children with cystic fibrosis.

Authors:  T J David
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

2.  Glucose tolerance in cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; G Erichsen; J Nerup; C Koch
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

3.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; V Launay; G A Loeuille; A Sardet; A Deschildre; D Druon; C Arrouet-Lagande
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

4.  Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.

Authors:  G Steinkamp; B Tümmler; R Malottke; H von der Hardt
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

5.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

6.  Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Authors:  Zackery P Bulman; Mark D Sutton; Neang S Ly; Jurgen B Bulitta; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 7.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

8.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.

Authors:  J L Gaillard; P Cahen; C Delacourt; C Silly; M Le Bourgeois; C Coustère; J de Blic; G Lenoir; P Scheinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

9.  Acute severe deterioration in cystic fibrosis associated with influenza A virus infection.

Authors:  S P Conway; E J Simmonds; J M Littlewood
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

10.  Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.

Authors:  H K Johansen; N Høiby
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.